Cargando…

No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats

Introduction: We previously reported that malignant hypertension is associated with impaired capillary density of target organs. Here, we tested the hypothesis that stabilization of hypoxia-inducible factor (HIF) in a modified “preconditioning” approach prevents the development of malignant hyperten...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartner, Andrea, Dambietz, Thomas, Cordasic, Nada, Willam, Carsten, Burzlaff, Nicolai, Brötsch, Martin, Daniel, Christoph, Schiffer, Mario, Amann, Kerstin, Veelken, Roland, Schley, Gunnar, Hilgers, Karl F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331609/
https://www.ncbi.nlm.nih.gov/pubmed/37435301
http://dx.doi.org/10.3389/fphys.2023.1208105
_version_ 1785070291427262464
author Hartner, Andrea
Dambietz, Thomas
Cordasic, Nada
Willam, Carsten
Burzlaff, Nicolai
Brötsch, Martin
Daniel, Christoph
Schiffer, Mario
Amann, Kerstin
Veelken, Roland
Schley, Gunnar
Hilgers, Karl F.
author_facet Hartner, Andrea
Dambietz, Thomas
Cordasic, Nada
Willam, Carsten
Burzlaff, Nicolai
Brötsch, Martin
Daniel, Christoph
Schiffer, Mario
Amann, Kerstin
Veelken, Roland
Schley, Gunnar
Hilgers, Karl F.
author_sort Hartner, Andrea
collection PubMed
description Introduction: We previously reported that malignant hypertension is associated with impaired capillary density of target organs. Here, we tested the hypothesis that stabilization of hypoxia-inducible factor (HIF) in a modified “preconditioning” approach prevents the development of malignant hypertension. To stabilize HIF, we employed pharmacological inhibition of HIF prolyl hydroxylases (PHD), that profoundly affect HIF metabolism. Methods: Two-kidney, one-clip renovascular hypertension (2K1C) was induced in rats; controls were sham operated. 2K1C rats received either intermittent injections of the PHD inhibitor ICA (2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate) or placebo. Thirty-five days after clipping, the frequency of malignant hypertension was assessed (based on weight loss and the occurrence of characteristic vascular lesions). In addition, kidney injury was compared between all ICA treated versus all placebo treated 2K1C, regardless of the occurrence of malignant hypertension. HIF stabilization was evaluated by immunohistochemistry, and HIF target gene expression by RT-PCR. Results: Blood pressure was elevated to the same degree in ICA- and placebo-treated 2K1C compared to control rats. ICA treatment did not affect the frequency of malignant hypertension or the extent of kidney tissue fibrosis, inflammation, or capillary density. There was a trend towards higher mortality and worse kidney function in ICA-treated 2K1C rats. ICA increased the number of HIF-1α-positive renal tubular cell nuclei and induced several HIF-1 target genes. In contrast, expression of HIF-2α protein as well as HIF-2 target genes were markedly enhanced by 2K1C hypertension, irrespective of ICA treatment. Discussion: We conclude that intermittent PHD inhibition did not ameliorate severe renovascular hypertension in rats. We speculate that the unexpected strong renal accumulation of HIF-2α in renovascular hypertension, which could not be further augmented by ICA, may contribute to the lack of a benefit from PHD inhibition.
format Online
Article
Text
id pubmed-10331609
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103316092023-07-11 No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats Hartner, Andrea Dambietz, Thomas Cordasic, Nada Willam, Carsten Burzlaff, Nicolai Brötsch, Martin Daniel, Christoph Schiffer, Mario Amann, Kerstin Veelken, Roland Schley, Gunnar Hilgers, Karl F. Front Physiol Physiology Introduction: We previously reported that malignant hypertension is associated with impaired capillary density of target organs. Here, we tested the hypothesis that stabilization of hypoxia-inducible factor (HIF) in a modified “preconditioning” approach prevents the development of malignant hypertension. To stabilize HIF, we employed pharmacological inhibition of HIF prolyl hydroxylases (PHD), that profoundly affect HIF metabolism. Methods: Two-kidney, one-clip renovascular hypertension (2K1C) was induced in rats; controls were sham operated. 2K1C rats received either intermittent injections of the PHD inhibitor ICA (2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate) or placebo. Thirty-five days after clipping, the frequency of malignant hypertension was assessed (based on weight loss and the occurrence of characteristic vascular lesions). In addition, kidney injury was compared between all ICA treated versus all placebo treated 2K1C, regardless of the occurrence of malignant hypertension. HIF stabilization was evaluated by immunohistochemistry, and HIF target gene expression by RT-PCR. Results: Blood pressure was elevated to the same degree in ICA- and placebo-treated 2K1C compared to control rats. ICA treatment did not affect the frequency of malignant hypertension or the extent of kidney tissue fibrosis, inflammation, or capillary density. There was a trend towards higher mortality and worse kidney function in ICA-treated 2K1C rats. ICA increased the number of HIF-1α-positive renal tubular cell nuclei and induced several HIF-1 target genes. In contrast, expression of HIF-2α protein as well as HIF-2 target genes were markedly enhanced by 2K1C hypertension, irrespective of ICA treatment. Discussion: We conclude that intermittent PHD inhibition did not ameliorate severe renovascular hypertension in rats. We speculate that the unexpected strong renal accumulation of HIF-2α in renovascular hypertension, which could not be further augmented by ICA, may contribute to the lack of a benefit from PHD inhibition. Frontiers Media S.A. 2023-06-26 /pmc/articles/PMC10331609/ /pubmed/37435301 http://dx.doi.org/10.3389/fphys.2023.1208105 Text en Copyright © 2023 Hartner, Dambietz, Cordasic, Willam, Burzlaff, Brötsch, Daniel, Schiffer, Amann, Veelken, Schley and Hilgers. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Hartner, Andrea
Dambietz, Thomas
Cordasic, Nada
Willam, Carsten
Burzlaff, Nicolai
Brötsch, Martin
Daniel, Christoph
Schiffer, Mario
Amann, Kerstin
Veelken, Roland
Schley, Gunnar
Hilgers, Karl F.
No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
title No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
title_full No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
title_fullStr No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
title_full_unstemmed No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
title_short No benefit of HIF prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
title_sort no benefit of hif prolyl hydroxylase inhibition for hypertensive renal damage in renovascular hypertensive rats
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331609/
https://www.ncbi.nlm.nih.gov/pubmed/37435301
http://dx.doi.org/10.3389/fphys.2023.1208105
work_keys_str_mv AT hartnerandrea nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT dambietzthomas nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT cordasicnada nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT willamcarsten nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT burzlaffnicolai nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT brotschmartin nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT danielchristoph nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT schiffermario nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT amannkerstin nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT veelkenroland nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT schleygunnar nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats
AT hilgerskarlf nobenefitofhifprolylhydroxylaseinhibitionforhypertensiverenaldamageinrenovascularhypertensiverats